19 March 2026
19 March 2026
The streamlined framework is part of the UK Government’s plans to ensure the life sciences sector reaches its full potential.
An expert involved in the first successful gene therapy trial for Huntington's Disease discusses the trial results and challenges with the FDA.
Backed by the venture portions of Eli Lily and Eisai, Excalipoint will look to progress the development of its six-strong TCE therapy pipeline.
A Gilead executive highlights limited investment in innovation against the need to speed up access to ATMPs.
Health secretary Wes Streeting is considering expanding the existing schedule to age groups beyond infants, such as teenagers.
At Advanced Therapies, investors noted that early planning, adaptability and building trust will help a biotech startup succeed.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
